Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 1Osteosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced or Metastatic Solid Tumors 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

pazopanib 2sintilimab 1sapanisertib 1pembrolizumab 1itacitinib 1baricitinib 1Trabectedin 1Radiotherapy, Intensity-Modulated 1Polymerase Chain Reaction 1Neoadjuvant Therapy 1INCB039110 1Gene Expression Profiling 1Doxorubicin 1Docetaxel 1Blotting, Western 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Histiocytoma, Malignant Fibrous × sintilimab × Clear all
NCT05017103 2024-12-11

Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study

M.D. Anderson Cancer Center

Phase 2 Terminated
6 enrolled 9 charts

Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡